About Us
EpiMedTechGlobal (EMTG) pioneers accessible healthcare solutions, envisioning a shift where groundbreaking innovations serve the well-being of individuals globally. Founded in 2016 by Prof. Moshe Szyf, a leader in epigenetics, our mission is clear: revolutionize healthcare through real-world applications for early disease detection. In cancer care, our epigenetics-driven blood tests exemplify accuracy and cost-effectiveness, aiming to unlock unprecedented potential for early detection and healthy aging. Beyond diagnosis, we emphasize prevention, a healthy lifestyle, and support for advancing epigenetics research, contributing to global health improvement.
Leadership
The leadership team of EpiMedTechGlobal (EMTG) boasts a range of expertise and PIONEERING accomplishments in the field of epigenetics:
Leading the company as Chairman, CEO and CSO is an epigenetic pioneer, Dr. Szyf holds prestigious positions including:
Read MoreMoshe Szyf, PhD
Founder of EpiMedTechGlobal (EMTG)
Leadership at EpiMedTechGlobal: Dr. Moshe Szyf, Epigenetics Pioneer
Dr. Moshe Szyf, serving as Chairman, CEO, and CSO, brings unparalleled expertise to EpiMedTechGlobal. His pioneering work in epigenetics has earned him prestigious titles and accolades:
- GlaxoSmithKline - CIHR Chair in Pharmacology and James McGill Professor, Department of Pharmacology and Therapeutics at McGill University.
- Fellowships in both the Royal Society of Canada and the Canadian Academy of Health Sciences.
- Inventor of the first patent in epigenetics and a founding figure in behavioral and psychiatric epigenetics.
- Author of around 300 influential papers and a sought-after speaker, including at the Nobel Forum and a TED Talk on DNA and early life experiences.
- Recognized as Quebec Scientist of the Year (2009) and featured in the NIMH Director's Innovation Speaker Series (2012), underscoring his impact on science and society.
Dr. Szyf's leadership and research continue to drive EpiMedTechGlobal towards groundbreaking discoveries and advancements in healthcare.
Serving as the Chief Innovation Officer, Dr. Cheishvili is recognized for his significant contributions to epigenetics both at the Hebrew University and at McGill University. He is currently the chief innovation officer leading the discoveries of new tests.
Read MoreDavid Cheishvili, Ph.D
Chief Innovation Officer
Medical Director has decades of experience as a director of CAP and CLIA regulated laboratories.
Read MoreDr Carlos Luiz
Medical Director
Heads the technology division, steering the development and implementation of innovative solutions. He brings to the company decades of experience in engineering and security of cloud based systems at Amdocs.
Read MoreLevan Cheishvili
Chief Technology Officer
Provides strategic guidance and oversight to the company's operations and direction. As an economist at the Bank of China and as a managing manager of a successful fund he brings decades of expertise in China financial ecosystem.
Read MoreYe Xiang, Ph.D.
Director and Member of the Board of Directors.
Leads Epiecho, a crucial division within HKG responsible for China operations, he brings years of expertise in the financial sector at Goldman and Sachs and as partner of a successful fund in HK. He is overseeing its strategic and operational activities.
Read MoreCharlie Ban
CEO of Epiecho
Oversees the clinical services offered by HKG, ensuring they meet the highest standards of care and effectiveness.
Read MoreSharon Luk, Ph.D.
Director of Clinical Services
Oversees the clinical services offered by EpiMedTechGlobal, ensuring they meet the highest standards of care and effectiveness.
With past experience at IFC, World Bank and the U.S. Travel Association in Washington DC, Aaron brings expertise in global finance, econometrics, research, financial modeling and travel/tourism. Aaron oversees the financial planning and financial activities of the company.
Read MoreAaron Szyf, BSc (Finance), MALD (Master of International Law and Diplomacy)
CFO
This team, with its blend of scientific, technological, and strategic expertise, drives EpiMedTechGlobal (EMTG) towards achieving its goals in medical innovation and early disease detection.
DNA Lab & Automation Team
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, apulvinar dapibus leo.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, apulvinar dapibus leo.
Advisory Board
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, apulvinar dapibus leo.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, apulvinar dapibus leo.
Prof. Shafaat A. Rabbani
(McGill University)
He is also associate member of Departments of Physiology at Oncology at McGill University Health Centre. Prof. Rabbani published more than 100 manuscripts 5899 citations, h index is 45 and i10 index is 84. Prof. Rabbani has served as expert reviewer for CIHR, CRS, CBCRA, DOD, US VA, Komen. Over the years Prof. Rabbani has served as a member of the scientific advisory board or consultant for various biotechnology and pharmaceutical companies like (Amgen, AstraZeneca, Axys, Attenuon, America Diagnostica, Procyon).
Read More
Prof. Shafaat A. Rabbani
(McGill University)
He is also associate member of Departments of Physiology at Oncology at McGill University Health Centre. Prof. Rabbani published more than 100 manuscripts 5899 citations, h index is 45 and i10 index is 84. Prof. Rabbani has served as expert reviewer for CIHR, CRS, CBCRA, DOD, US VA, Komen. Over the years Prof. Rabbani has served as a member of the scientific advisory board or consultant for various biotechnology and pharmaceutical companies like (Amgen, AstraZeneca, Axys, Attenuon, America Diagnostica, Procyon).
Read More
Invest in the future of healthcare
Invest in the future of healthcare
Would you like to play a pivotal role in longevity and global health?
Our emphasis on epigenetics, preventive healthcare, and cutting-edge diagnostics underscores the transformative potential of HKG Epitherapeutics. Investing in our endeavors aligns with a vision to save lives, promote healthy aging, and contribute to a resilient and healthier global community.
Investors Resources
White Paper
Eliquam magna massa, gravida finibus fermentum sit amet
Industry Report
Eliquam magna massa, gravida finibus fermentum sit amet
Along with his lifelong commitment to uncovering hypotheses and then making them work, Moshe Szyf still carves out the time to share his groundbreaking innovations by contributing to the widely-popular, highly-respected TED talks which are viewed 1.5 million times a day.
